Janus
Log In
Log Out
Ticker Symbol:
JNGLX
Fund Type:
  

Management Fee Evaluation


Class D shares

   
Who should consider this fund

Investors looking for exposure to a fast-growing area of the overall market through companies that we believe are either driving advancements in the healthcare field or benefiting from demographic trends

  • Global approach to companies that are addressing unmet medical needs and providing efficient and cost-effective healthcare solutions
  • Differentiated fundamental research -- we seek to understand the science and the business
  • Disciplined valuation analysis and diversification across industries, geographies and market capitalization
Andrew Acker
  • Joined Janus in 1999
  • Andrew is a CFA Charterholder
  • Bachelor's degree - biochemical sciences, Harvard College, graduating magna cum laude and Phi Beta Kappa
  • M.B.A. from Harvard Business School

 

 

as of 03/31/2014
More

Please consider the charges, risks, expenses and investment objectives carefully before investing. Please see a prospectus , or if available, a summary prospectus containing this and other information. Read it carefully before you invest or send money.

A Fund's performance may be affected by risks that include those associated with nondiversification, non-investment grade debt securities, high-yield/high-risk securities, undervalued or overlooked companies, investments in specific industries or countries and potential conflicts of interest. Additional risks to a Fund may also include, but are not limited to, those associated with investing in foreign securities, emerging markets, initial public offerings, real estate investment trusts (REITs), derivatives, short sales, commodity-linked investments and companies with relatively small market capitalizations. Each Fund has different risks. Please see a Janus prospectus for more information about risks, Fund holdings and other details.

Foreign securities have additional risks including exchange rate changes, political and economic upheaval, the relative lack of information, relatively low market liquidity and the potential lack of strict financial and accounting controls and standards. These risks are magnified in emerging markets. The prices of foreign securities held by the fund, and therefore a fund's performance, may decline in response to such risks.

The use of short sales may cause the fund to have higher expenses than those of other equity funds. Short sales are speculative transactions and involve special risks, including a greater reliance on the investment team's ability to accurately anticipate the future value of a security. The Fund's losses are potentially unlimited in a short sale transaction. The Fund's use of short sales in effect leverages the Fund's portfolio. The Fund's use of leverage may result in risks and can magnify the effect of any losses. There is no assurance that a leveraging strategy will be successful.

The Fund will normally invest at least 80% of its net assets, measured at the time of purchase, in the type of securities described by its name.

Holdings are subject to change without notice.

Janus Distributors LLC